Damora Therapeutics (DMRA) Non-cash Items (2020 - 2026)

Damora Therapeutics has reported Non-cash Items for 6 years, with the latest figure at $11.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items changed N/A year-over-year to $11.4 million; the trailing twelve-month figure through Mar 2026 stood at $11.4 million (changed N/A YoY), and the FY2025 full-year result was $8.5 million, changed N/A from the prior year.
• Non-cash Items for Q1 2026 stood at $11.4 million, up from $8.5 million in the prior quarter.
• The five-year high for Non-cash Items was $11.4 million in Q1 2026, with the low at $2400.0 in Q3 2022.
• Historically, Non-cash Items has averaged $4.2 million across 4 years, with a median of $2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Non-cash Items tumbled 99.81% — and 2023, when it jumped 320.32%.
• Damora Therapeutics' Non-cash Items stood at $2400.0 in 2022, then soared by 135575.38% to $3.3 million in 2023, then surged by 160.35% to $8.5 million in 2025, then surged by 34.73% to $11.4 million in 2026.
• The last three Non-cash Items figures came in at $11.4 million (Q1 2026), $8.5 million (Q4 2025), and $3.3 million (Q2 2023), per Business Quant data.